Kymera Q1 net loss $65.6M, cash $775M; unveils oral IRF5 degrader KT-579; STAT6 data June

Kymera Therapeutics, Inc.

2025-Q1 EPS reported -$0.82 revenue$22,100,000

Net loss $65.6M (Q1 2025) vs $48.6M (Q1 2024); collab revenue $22.1M incl $20M Sanofi milestone.
Cash $775M as of Mar 31, 2025; runway extended into H1 2028.
KT-621 (STAT6) Ph1 SAD/MAD healthy volunteer data due June 2025; BroADen Ph1b in AD started, data 4Q25.
New oral IRF5 degrader KT-579 unveiled; IND-enabling ongoing, Phase 1 expected early 2026.
Strategic decision to not advance KT-295 (TYK2) into clinic; focus on STAT6 and IRF5.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.